Ben McDonald Joins Median Technologies’ Board of Directors

Median Technologies has appointed Ben McDonald to its Board of Directors, chaired by Oran Muduroglu. 
 
McDonald is a co-founder, partner, and chief investment officer at Aegis Group Partners, a frontier technologies investment firm. He oversees Aegis Group Partners’ investments in various industries, including artificial intelligence, software, biotech, quantum computing, biomaterials, and clean tech. 

“I’m thrilled to welcome Ben McDonald to the board of directors of Median Technologies. As a co-founder, partner, and chief investment officer at Aegis Group Partners managing the Celestial Successor Fund, Ben is a long-lasting shareholder of our company and has played an instrumental role during our last round of fundraising in July 2023. Ben’s profound knowledge of the U.S. health tech sector as well as his strong commitment in supporting health tech companies and startups are a real asset for Median and will very nicely complement our BOD’s expertise,” Median Technologies Founder/CEO Fredrik Brag said.
 
McDonald serves on the Board of Directors for Aegis Group Partners Holdco, Noble Biomaterials, SuperTurbo Technologies, and Next Generation Turbo. He also served on the Board of Directors of Introhive before its sale to Providence Strategic Growth. Prior to joining Aegis Group Partners, McDonald was an investor at Citadel Global Equities and Ailanthus Capital Management, where he focused on the technology sector.

McDonald earned an MBA from the University of Cambridge and an HBA from Western University.
 
“I am delighted to join the board of directors at Median Technologies. The company has a track record in pioneering cutting-edge technologies, particularly in the field of non-invasive AI-based imaging biomarkers. These biomarkers play an essential role in the emerging era of personalized and predictive medicine, allowing physicians to create bespoke treatment plans for patients, resulting in improved healthcare outcomes and a reduction in unnecessary invasive procedures,” McDonald stated. “I firmly believe that Median’s unwavering dedication to innovation and excellence will create significant value for patients, hospitals, insurers, and investors alike.”
 
Median Technologies provides imaging solutions and services. It harnesses the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the diagnosis and treatment accuracy of many cancers and other metabolic diseases and provide insights into novel therapies for patients. Median Technologies’ iCRO solutions for medical image analysis and management in oncology trials and iBiopsy, its AI/ML tech-based suite of software as medical devices (SaMD), help companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. 

Founded in 2002, based in Sophia-Antipolis, France, with a U.S. subsidiary and another in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris).